The application of biomarkers in hereditary transthyretin amyloidosis – an ongoing research project on bulgarian patients
DOI:
https://doi.org/10.67667/NEU.v25i1.158Keywords:
neurofilaments, hereditary transthyretin amyloidosis, vATTR, NfLAbstract
The current research project is being conducted in IMDL Genome Center Bulgaria / GMDL Genica (part of the Expert Centers for ATTR in Bulgaria1). It aims at advancing the accurate prognosis and monitoring of the onset and progression of hereditary transthyretin amyloidosis (vATTR) in Bulgarian Glu89Gln positive asymptomatic and symptomatic polyneuropathy stage I patients on Tafamidis by investigating the biomarker potential of NfL. Furthermore, our goal is to evaluate other better-known biomarkers for cardiac affection such as hs-cTnT, NT-ProBNP and eGFR. In so doing, our multidisciplinary team aims to improve the processes of timely diagnosis and therapy of the Bulgarian vATTR patient community.
References
Nakov, R., Sarafov, S., Gospodinova, M. et al. Transthyretin amyloidosis: Testing strategies and model for center of excellence support. Clin Chim Acta Int J Clin Chem. 2020, 509, 228-234.
Chamova, T., Gospodinova, M., Asenov, O. et al. Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria. Front Neurol. 2022, 13, 844595.
Gospodinova, M., Kinova, E., Simova, I. et al. Diagnostic algorithm in transthyretin amyloidosis with cardiomyopathy. Bulg Cardiol. 2020, 26, 5-20.
Eyer, J., Peterson, A. Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-beta-galactosidase fusion protein. Neuron. 1994, 12, 2, 389-405.
Yum, S.W., Zhang, J., Mo, K., Li, J., Scherer, S.S. A Novel Recessive NEFL Mutation Causes a Severe, Early-Onset Axonal Neuropathy. Ann Neurol. 2009, 66, 6, 759-770.
Yuan, A., Sasaki, T., Kumar, A. et al. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci Off J Soc Neurosci. 2012, 32, 25, 8501-8508.
Khalil, M., Teunissen, C.E., Otto, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018, 14, 10, 577-589.
Lundberg, M., Eriksson, A., Tran, B., Assarsson, E., Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011, 39, 15, 102.
Ticau, S., Aldinc, E., Polydefkis, M. et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. Published online July 20, 2023, 1-11.
Takashio, S., Yamamuro, M., Izumiya, Y. et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2017, 5, 1, 27-35.
Castiglione, V., Aimo, A., Vergaro, G., et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022, 27, 2.
Lehrke, M., Becker, A., Greif, M. et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009, 161, 2, 339-344.
Gillmore, J.D., Damy, T., Fontana, M. et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018, 39, 30, 2799-2806.
Grogan, M., Scott, C.G., Kyle, R.A. et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016, 68, 10, 1014-1020.
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2024 Z. Pavlova, A. Ormandjieva, C. Georgiev, O. Asenov, A. Taneva, T. Chamova, I. Tournev, Albena Todorova
This work is licensed under a Creative Commons Attribution 4.0 International License.
